Andrew Hill from Liverpool University and colleagues presented the first analysis of predicted generic costs for ribavirin and four DAAs that are currently in late phase development daclatasvir, sofosbuvir, faldaprevir and simeprevir based on compound properties including chemical structure, complexity of synthesis, daily dose etc, and then adapted manufacturing costs achieved by ARV access programmes from the Clinton Foundation and MSF.
For HIV drugs, the minimum manufacturing costs (per gram) by drug class ranged from $0.2 for NNRTIs, $0.2-1.0 for nucleoside analogues and $0.5 for nucleotide analogues to $1.0-$2.1 for protease inhibitors.
This resulted in predicted cost for 12-week treatment of $20-63 for ribavirin, $10-30 for daclatasvir, $68-136 for sofosbuvir, $100-210 for faldaprevir and $130-270 for simeprevir, see Table 1. There has already been encouraging study results using declatasvir plus sofosbuvir and sofosbuvir is also being studied with simeprevir.
The poster concluded that large scale production of a combination of ribavirin plus two DAAs might be achievable at $100-200 per person within 15 years given patent expiry dates for the new drugs are from 2026-2029.
From a global health perspective, the urgency for establishing initiatives such as the patent pool for hepatitis C drugs and political pressure for much earlier access should make such a deferred timeline unacceptable.
|Table 1. Predicted minimum cost per person for 12 week course of DAA|
|HCV DAA||Patent expiry||Class/daily dose||Total dose (12 wk)||Predicted cost (US $)|
Links to other websites are current at date of posting but not maintained.
- Hill A et al.What is the minimum cost per person to cure HCV?7th IAS Conference on HIV Pathogenesis, Treatment and Prevention, 30 June 3 July 2013, Kuala Lumpur. Late breaker poster TULBPE16.